ABOUT PMC

An educational and advocacy organization, PMC promotes personalized medicine by addressing regulatory, reimbursement and clinical adoption issues critical to the field. Based on the diversity of its membership, PMC has become the preeminent source of knowledge about personalized medicine and a force for shaping policy about and increasing investment in the field.

The Coalition:

• **Provides opinion leadership** on policy issues that affect personalized medicine;

• **Helps educate policymakers** in government, industry and academia about the benefits of personalized medicine; and

• **Serves as a forum** for identifying and informing others of policies that could advance or impede the development of personalized medicine.
The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system.

**BENEFITS OF MEMBERSHIP**

By joining PMC, organizations gain an opportunity to shape the future of the field by:

- **Having a voice in creating a favorable policy environment** for personalized medicine;
- **Forging relationships** with other stakeholders in personalized medicine; and
- **Sharing best practices**
  - Educational resources
  - Forums for debate and consensus driven solutions
  - Networking within and across domains

Members also learn about the latest trends and developments in science, policy and business through forums, newsletters and member-only updates.

Personalized medicine is transforming the practice of medicine, and the Personalized Medicine Coalition is playing a critical role in bringing together all of the stakeholders to help make that happen.

Raju Kucherlapati, Ph.D.
Paul C. Cabot Professor of Genetics
Professor of Medicine
Harvard Medical School
The Role of the Personalized Medicine Coalition

Paradigm shifts, especially in medicine, do not happen just because the science or new technologies suggest they should. Based on that assumption, at the end of 2004, the Personalized Medicine Coalition (PMC) was launched by some 20 institutions, which spanned the health care ecosystem. They included the pharmaceutical, biotechnology and diagnostic industries, tool manufacturers, academic health centers, venture capitalists, insurance companies and patient advocates.

With the growth of personalized medicine over the past decade, the Coalition has expanded to include more than 250 institutions across the health care spectrum. Along with raising personalized medicine’s profile, PMC advocates for changes that will increase investment in personalized medicine and facilitate its adoption so that both patients and the health system will benefit from improved clinical care and increased overall value.

What is Personalized Medicine?

Personalized medicine is an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each patient. By combining the data from those tests with an individual’s medical history, circumstances and values, health care providers can develop targeted treatment and prevention plans.
A 501(c)3 organization, PMC is an independent, non-partisan educational and advocacy organization with members that are committed to science-driven, evidence-based health care.

**CLINICAL LABORATORY TESTING SERVICES**
- AlphaGenomix Laboratories
- Centro de Genomas
- Clinical Reference Laboratory, Inc.
- Empire Genomics
- Laboratory Corporation of America (LabCorp)
- Metabolon, Inc.
- Millennium Health
- PCLS
- Proove Biosciences
- Quest Diagnostics

**DIAGNOSTIC COMPANIES**
- Abbott
- Adaptive Biotechnologies
- Agendia NV
- Alacris Theranostics GmbH
- Almac Diagnostics
- AltheaDX
- Assurex Health, Inc.
- ASURAGEN, Inc.
- BD (Becton Dickinson & Company)
- Biodesix
- Biological Dynamics, Inc.
- Brain Resource Company Limited
- Captron Proteomics
- CareRx, Inc.
- Caris Life Sciences
- Counsyl
- Epic Sciences, Inc.
- Exact Sciences Corporation
- Exosome Diagnostics
- Foundation Medicine, Inc.
- GeneCentric Diagnostics
- Genomic Health, Inc.
- Helomics
- Human Longevity
- Indi – Integrated Diagnostics
- Invata
- Interleukin Genetics, Inc.
- Invivoscribe Technologies, Inc.
- Leica Biosystems
- Luminex Corporation
- Metamark Genetics, Inc.
- MolecularMD
- NanoString Technologies
- Novodiax
- OncoPlex Diagnostics
- Personal Genome Diagnostics (PGDx)
- Qiagen, Inc.
- Roche Diagnostics
- Seegene TECHNOLOGIES, Inc.
- Siemens Healthcare Diagnostics, Inc.
- SomaLogic, Inc.
- Strand Genomics, Inc.
- SurExam
- Vermillion
- **EMERGING BIOTECH/PHARMACEUTICAL COMPANIES**
- Altan Pharma Ltd.
- Syros Pharmaceuticals
- Zinfandel Pharmaceuticals, Inc.
- **HEALTH INSURANCE COMPANIES**
- Aetna
- **INDUSTRY/TRADE ASSOCIATIONS**
- American Clinical Laboratory Association
- BIO (Biotechnology Innovation Organization)
- PhRMA
- **IT/INFORMATICS COMPANIES**
- 5AM Solutions, Inc.
- athenahealth
- Cytalon AG
- DNA nexus
- Emdeon
- Flatiron Health
- Genospace
- GNS Healthcare
- Inspire
- Intel Corporation
- M2Gen
- McKesson
- NextQdx
- Oracle Health Sciences
- Seven Bridges
- Syapse
- UNIConnect, LC
- XIFIN, Inc.
- **LARGE BIOTECH/PHARMACEUTICAL COMPANIES**
- AbbVie
- Amgen, Inc.
- Astellas Pharma Global Development
- AstraZeneca
- Boehringer-Ingelheim Pharmaceuticals, Inc.
- Bristol-Myers Squibb
- Eli Lilly and Company
- EMD Serono
- Endo Health Solutions
- GE Healthcare
- Genentech, Inc.
- GlaxoSmithKline, PLC
- Johnson & Johnson
- Takeda Pharmaceuticals International Company
- Teva
- Novartis
- Pfizer, Inc.

**PATIENT ADVOCACY GROUPS**
- Accelerated Cure Project for Multiple Sclerosis
- Alliance for Aging Research
- Bonnie J. Addario Lung Cancer Foundation
- Bulgarian Association for Personalized Medicine
- Cancer Commons
- Friends of Cancer Research Global Liver Institute
- HealthyWomen International Cancer Advocacy Network ("ICAN")
- LUNGevity Foundation
- Melanoma Research Alliance Foundation
- Multiple Myeloma Research Foundation
- National Alliance for Hispanic Health
- National Brain Tumor Society
- National Patient Advocate Foundation
- One Disease at a Time

**PERSONALIZED MEDICINE SERVICE PROVIDERS**
- 23andMe
- Advanced Individualized Medicine
- Cure Forward
- Health Decisions
- InformedDNA
- Intervention Insights
- KEGW Group
- Michael J. Bauer, M.D., & Associates, Inc.
- MolecularHealth
- MolecularMatch
- NantOncis
MEMBERSHIP APPLICATION

ORGANIZATION NAME

ADDRESS

CITY  STATE  ZIP

COUNTRY

PHONE  FAX

PRIMARY CONTACT NAME

EMAIL

MEMBER LIST CATEGORY
Please select the appropriate member list category:

☐ Clinical Laboratory Testing Services
☐ Diagnostic Companies
☐ Emerging Biotech/Pharmaceutical Companies
☐ Health Insurance Companies
☐ Industry and Trade Associations
☐ IT/Informatics Companies
☐ Large Biotech/Pharmaceutical Companies
☐ Patient Advocacy Groups
☐ Personalized Medicine Service Providers
☐ Research, Education & Clinical Care Institutions
☐ Research Tool Companies
☐ Strategic Partners
☐ Venture Capital Firms

ORGANIZATION TYPE/DUES
Please select the appropriate annual dues structure:

☐ Large Corporation  $26,250
☐ Small Public Corporation  $13,125
☐ Trade Association  (based on revenues)
☐ Private Corporation >50 FTEs  $5,250
☐ Private Corporation <50 FTEs  $3,150
☐ Professional Society  $5,250
☐ Strategic Partner  $2,625
☐ Research, Education & Clinical Care Institutions  $2,625
☐ Venture Capital Firm  $2,625
☐ Patient Advocacy Group  $525

Amount $  Check #

Mail completed application and payment to:
Personalized Medicine Coalition
1710 Rhode Island Avenue, NW, Suite 700
Washington, DC 20036